Hyperion Therapeutics, Inc. (HPTX):企業の財務及び戦略的SWOT分析

【英語タイトル】Hyperion Therapeutics, Inc. (HPTX) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(GDPH138030FSA)・商品コード:GDPH138030FSA
・発行会社(調査会社):GlobalData
・発行日:2015年3月17日
・ページ数:57
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:アメリカ
・産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single UserUSD125 ⇒換算¥14,125見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD250 ⇒換算¥28,250見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD375 ⇒換算¥42,375見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Hyperion Therapeutics, Inc. (HPTX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Hyperion Therapeutics, Inc. (Hyperion) is a biopharmaceutical company. It develops and commercializes novel drugs for the treatment of orphan diseases and hepatology disorders. Ravicti, the company’s first approved product is indicated for use as a nitrogen-binding agent in adult and pediatric patients aged above two years suffering with urea cycle disorders (UCDs) and those who cannot be treated by dietary protein restriction and amino acid supplementation alone. Ravicti (glycerol phenylbutyrate) lowers ammonia in the blood. The product is also being developed for a second orphan indication, hepatic encephalopathy (HE)

Hyperion Therapeutics, Inc. Key Recent Developments

Feb 26, 2015 Hyperion Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results
Dec 18, 2014 Hyperion Therapeutics Added to Nasdaq Biotechnology Index
Nov 06, 2014 Hyperion Therapeutics Announces Third Quarter 2014 Financial Results
Aug 12, 2014 Hyperion Therapeutics Appoints Theodore Schroeder to Board of Directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 – About the Company 6
Hyperion Therapeutics, Inc. – Key Facts 6
Hyperion Therapeutics, Inc. – Key Employees 7
Hyperion Therapeutics, Inc. – Key Employee Biographies 8
Hyperion Therapeutics, Inc. – Major Products and Services 10
Hyperion Therapeutics, Inc. – Pharmaceutical Pipeline Products Data 11
Hyperion Therapeutics, Inc., Pipeline Products by Therapy Area 11
Hyperion Therapeutics, Inc., Pipeline Products by Development Phase 12
Hyperion Therapeutics, Inc. – History 14
Hyperion Therapeutics, Inc. – Company Statement 17
Hyperion Therapeutics, Inc. – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Section 2 – Company Analysis 21
Hyperion Therapeutics, Inc. – Business Description 21
Hyperion Therapeutics, Inc. – Corporate Strategy 22
Hyperion Therapeutics, Inc. – SWOT Analysis 23
SWOT Analysis – Overview 23
Hyperion Therapeutics, Inc. – Strengths 23
Strength – Unique Product – Ravicti 23
Strength – Product Acquisition 23
Strength – Focused Research and Development Activities 23
Hyperion Therapeutics, Inc. – Weaknesses 24
Weakness – History of Losses 24
Weakness – Reliance on Third Parties 24
Weakness – Discontinuation of Product in Development 24
Hyperion Therapeutics, Inc. – Opportunities 25
Opportunity – Limited Therapies for Urea Cycle Disorders 25
Opportunity – Orphan Drug Designation 25
Opportunity – GPB Candidate in Clinical Development 25
Hyperion Therapeutics, Inc. – Threats 26
Threat – Uncertain R&D Outcomes 26
Threat – Competitive Pressures 26
Threat – Stringent Government Regulations 26
Hyperion Therapeutics, Inc. – Key Competitors 27
Section 3 – Company Financial Ratios 28
Financial Ratios – Capital Market Ratios 28
Financial Ratios – Annual Ratios 29
Performance Chart 31
Financial Performance 31
Financial Ratios – Interim Ratios 32
Financial Ratios – Ratio Charts 33
Section 4 – Company’s Lifesciences Financial Deals and Alliances 34
Hyperion Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 34
Hyperion Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 35
Hyperion Therapeutics, Inc., Recent Deals Summary 36
Section 5 – Company’s Recent Developments 37
Feb 26, 2015: Hyperion Therapeutics Announces Fourth Quarter and Full Year 2014 Financial Results 37
Dec 18, 2014: Hyperion Therapeutics Added to Nasdaq Biotechnology Index 39
Nov 06, 2014: Hyperion Therapeutics Announces Third Quarter 2014 Financial Results 40
Aug 12, 2014: Hyperion Therapeutics Appoints Theodore Schroeder to Board of Directors 43
Aug 07, 2014: Hyperion Therapeutics Announces Second Quarter 2014 Financial Results 44
Aug 06, 2014: Minister Ambrose Announces Patient Involvement Pilot for Orphan Drugs 47
May 06, 2014: Hyperion Therapeutics Announces First Quarter 2014 Financial Results 48
Feb 27, 2014: Hyperion Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results 50
Jan 08, 2014: Hyperion Therapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference 52
Section 6 – Appendix 53
Methodology 53
Ratio Definitions 53
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Hyperion Therapeutics, Inc., Key Facts 6
Hyperion Therapeutics, Inc., Key Employees 7
Hyperion Therapeutics, Inc., Key Employee Biographies 8
Hyperion Therapeutics, Inc., Major Products and Services 10
Hyperion Therapeutics, Inc., Number of Pipeline Products by Therapy Area 11
Hyperion Therapeutics, Inc., Number of Pipeline Products by Development Stage 12
Hyperion Therapeutics, Inc., Pipeline Products By Therapy Area and Development Phase 13
Hyperion Therapeutics, Inc., History 14
Hyperion Therapeutics, Inc., Subsidiaries 20
Hyperion Therapeutics, Inc., Key Competitors 27
Hyperion Therapeutics, Inc., Ratios based on current share price 28
Hyperion Therapeutics, Inc., Annual Ratios 29
Hyperion Therapeutics, Inc., Interim Ratios 32
Hyperion Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 34
Hyperion Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 35
Hyperion Therapeutics, Inc., Recent Deals Summary 36
Currency Codes 53
Capital Market Ratios 53
Equity Ratios 54
Profitability Ratios 54
Cost Ratios 55
Liquidity Ratios 55
Leverage Ratios 56
Efficiency Ratios 56

List of Figures
Hyperion Therapeutics, Inc., Pipeline Products by Therapy Area 11
Hyperion Therapeutics, Inc., Pipeline Products by Development Phase 12
Hyperion Therapeutics, Inc., Performance Chart (2010 - 2014) 31
Hyperion Therapeutics, Inc., Ratio Charts 33
Hyperion Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 34
Hyperion Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 35

★調査レポート[Hyperion Therapeutics, Inc. (HPTX):企業の財務及び戦略的SWOT分析] (コード:GDPH138030FSA)販売に関する免責事項を必ずご確認ください。
★調査レポート[Hyperion Therapeutics, Inc. (HPTX):企業の財務及び戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆